18F-FDG PET/MRI与哨兵淋巴结活检用于早期乳腺癌腋窝分期:一项前瞻性单臂试验
这项前瞻性单臂单中心试验纳入246例术前标准影像腋窝阴性、适合 upfront 手术的乳腺癌患者,术前行18F-FDG PET/MRI并由盲法阅片者独立判读,评估其检测腋窝宏转移的准确性;结果显示PET/MRI检出61例宏转移中的43例(70.5%),阴性预测值89.4%,优于单独PET或MRI。
要点
- 在临床腋窝阴性的早期乳腺癌患者中,18F-FDG PET/MRI检出70.5%的腋窝宏转移病例。
- PET/MRI对宏转移的检出率高于单独18F-FDG PET(59.0%,p=0.016)和单独MRI(41.0%,p<0.001)。
- PET/MRI的阴性预测值(89.4%)高于单独PET(86.4%,p=0.021)和单独MRI(82.9%,p<0.001)。
核心结论
- 在临床腋窝阴性的早期乳腺癌患者中,18F-FDG PET/MRI检出70.5%的腋窝宏转移病例,准确性高于单独18F-FDG PET或单独MRI。
- 作者认为先进影像可能有助于优化腋窝分期的手术策略。
研究设计与样本
- 前瞻性介入性单臂单中心试验,纳入标准术前影像无淋巴结受累且适合 upfront 手术的乳腺癌患者。
- 2020年6月至2024年4月期间招募患者,术前接受18F-FDG PET/MRI检查。
- 两名放射科医生和两名核医学医生在盲法下独立阅片。
- 共纳入246例患者,其中5例为双侧病变,最终评估251个腋窝;手术时平均(SD)年龄56.3(10.7)岁,最终病理平均(SD)肿瘤大小17.5(13.0)mm。
主要发现
- 61例(24.3%)发现腋窝宏转移淋巴结。
- 18F-FDG PET/MRI识别其中43例(70.5%)。
- 18F-FDG PET识别36例(59.0%;p=0.016),MRI识别25例(41.0%;p<0.001),PET/MRI检出率显著优于两者。
- PET/MRI阴性预测值为89.4%,高于单独PET的86.4%(p=0.021)和单独MRI的82.9%(p<0.001)。
关键数值与推荐
- PET/MRI检出腋窝宏转移43/61例(70.5%),单独PET检出36/61例(59.0%,p=0.016),单独MRI检出25/61例(41.0%,p<0.001)。
- PET/MRI阴性预测值89.4%,单独PET 86.4%(p=0.021),单独MRI 82.9%(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为先进影像可能有助于优化腋窝分期的手术策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two randomized controlled trials demonstrated the non-inferiority of axillary surgery omission in selected early breast cancer patients. However, clinicians remain hesitant to forgo sentinel lymph node biopsy due to its potential therapeutic implications. A reliable imaging modality for nodal metastases detection could potentially replace surgery. This trial prospectively evaluated the accuracy of hybrid [18F]FDG PET/MRI in detecting axillary lymph nodes macro-metastases in women with early breast cancer. METHODS: This is a prospective interventional single-arm monocentric trial including patients with breast cancer without nodal involvement on standard preoperative imaging and eligible for upfront surgery. Between June 2020 and April 2024 recruited patients underwent [18F]FDG PET/MRI before surgery. Two radiologists and two nuclear medicine physicians, all blinded, independently reviewed the images. FINDINGS: A total of 246 patients were included. Five had bilateral disease, leading to the evaluation of 251 axillae. Mean (SD) age at surgery was 56.3 (10.7) years and mean (SD) tumor size was 17.5 (13.0) mm at final pathology. Macro-metastatic axillary lymph nodes were found in 61 cases (24.3 %). [18F]FDG PET/MRI identified 43 (70.5 %) of these cases, and significantly outperformed both [18F]FDG PET and MRI alone, which identified 36 (59.0 %; p = 0.016) and 25 (41.0 %; p < 0.001) cases, respectively. Negative predictive value was higher for [18F]FDG PET/MRI (89.4 %) than [18F]FDG PET (86.4 %, p = 0.021) and MRI (82.9 %, p0.001 <) alone. INTERPRETATIONS: [18F]FDG PET/MRI detected 70.5 % of cases with macro-metastatic axillary lymph nodes in patients with clinically negative axilla, with greater accuracy than [18F]FDG PET or MRI alone. Advanced imaging might help refine the surgical strategy for axillary staging. TRIAL REGISTRATION: ClinicalTrials.Gov ID NCT04829643.
引用
- Di Micco R, Botteri E, Canevari C, et al. [18F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial. Eur J Cancer. 2025. PMID: 40449294. doi:10.1016/j.ejca.2025.115519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。